medigraphic.com
Academia Mexicana de Neurología, A.C.

2018, Number 6

<< Back Next >>

Rev Mex Neuroci 2018; 19 (6)

Clinical relevance of GABAB receptors in the drug addiction treatment

Cedillo-Zavaleta LN, Ruíz-García I, Jiménez-Mejía JC, Miranda-Herrera F

Language: Spanish
References: 52
Page: 32-42
PDF size: 461.64 Kb.


ABSTRACT

The γ-aminobutyric-acid (GABA) is the main inhibitory neurotransmitter in the human central nervous system (CNS) and produces activation of three distinct classes of GABA receptors. The GABAB receptor is an heterodimer with two 7TM subunits, it was characterized in the 70’s of the 20th century and it was largely studied regarding its relation with several pathologies. GABAB receptors are widely distributed throughout the CNS, however, in the addiction field, the GABAB receptors on the ventral tegmental area (VTA) dopaminergic neurons body have generated a large number of researches. GABAB receptors activation produces inhibition of the VTA dopaminergic neurons and the dopamine release decrease in the accumbens, the main component of the reward system. Due to his complexity and his important role on the addiction treatment, in this paper we review general aspects about GABA, like its discovery, synthesis, receptors and signaling pathways, besides experimental and clinical evidence that support or limit the therapeutic use of GABAB receptor agonists for addictions.


REFERENCES

  1. Consejo Nacional Contra las Adicciones. Encuesta Nacional de Adicciones 2011. México: Secretaría de Salud; 2012.

  2. Cryan JF, Kaupmann K. Don’t worry ‘B’ happy!: a role for GABAB receptors in anxiety and depression. Trends Pharmacol Sci. 2005;26(1):36-43.

  3. Knapp DJ, Overstreet DH, Breese GR. Baclofen blocks expression and sensitization of anxiety-like behavior in an animal model of repeated stress and ethanol withdrawal. Alcohol Clin Exp Res. 2007;31(4):582-95.

  4. Stratford TR, Kelley AE. GABA in the nucleus accumbens shell participates in the central regulation of feeding behavior. J Neurosci. 1997; 17(11):4434-40.

  5. Agabio R, Colombo G. GABAB receptor as therapeutic target for drug addiction: from baclofen to positive allosteric modulators. Psychiatr Pol. 2015;49(2):215-23.

  6. Roberts E, Frankel S. Gamma-aminobutyric acid in brain: its formation from glutamic acid. J Biol Chem. 1950;187(1):55-63.

  7. Bowery NG, Smart TG. GABA and glycine as neurotransmitters: a brief history. Br J Pharmacol. 2006;147 Suppl 1:109-19.

  8. Florey E. A new test preparation for bio-assay of factor I and gamma-aminobutyric acid. J Physiol. 1961;156:1-7.

  9. Hill RG, Simmonds MA, Straughan DW. Evidence that bicuculline can both potentiate and antagonize GABA. Br J Pharmacol. 1971;42(4):639-40.

  10. Jackel C, Krenz WD, Nagy F. Bicuculline/baclofen-insensitive GABA response in crustacean neurons in culture. J Exp Biol. 1994;191(1): 167-93.

  11. Hill DR, Bowery NG. 3H-baclofen and 3H-GABA bind to bicuculline-insensitive GABAB sites in rat brain. Nature. 1981;290:149-52.

  12. Feldman RS, Meyer JS, Quenzer LF. Principles of Neuropsychopharmacology. Massachussets: Sinauer; 1996.

  13. DeRuiter J. GABAminergic neurotransmission: Introduction. Principles of drug addiction. 2004;1-12.

  14. Wang M. Neurosteroids and GABA-A receptor function. Front Endocinol (Lausanne). 2011;2:44.

  15. Bowery NG. A brief history of the GABAB receptor. En: Colombo G, editor. GABAB receptor. Suiza: Humana Press; 2016. p. 1-13.

  16. Filip M, Frankowska M. GABAB receptors in drug addiction. Pharmacol Rep. 2008;60(6):755-70.

  17. Chebib M, Johnston GARJ. The ‘ABC’ of GABA receptors: a brief review. Clinical and experimental. Clin Exp Pharmacol Physiol. 1999;26(11):937-40.

  18. Bettler B, Kaupmann K, Mosbacher J, Gassmann M. Molecular structure and physiological functions of GABAB receptors. Physiol Rev. 2004;84(3):835-67.

  19. Di Chara G, Bassareo V. Reward system and addiction: what dopamine does and doesn’t do. Curr Opin Pharmacol. 2007;7(1):69-76.

  20. Smith AD, Olson RJ, Justice JB. Quantitative microdialysis of dopamine in the striatum: effect of circadian variation. J Neurosci Methods. 1992;44(1):33-41.

  21. Fiorino DF, Phillips AG. Facilitation of sexual behavior and enhanced dopamine efflux in the nucleus accumbens of male rats after D-Amphetamine- induced behavioral sensitization. J Neurosci. 1999;19(1):456-63.

  22. Volkow ND, Morales M. The brain on drugs: from reward to addiction. Cell. 2015;162(4):712-25.

  23. Cousins MS, Roberts DC, de Wit H. GABAB receptor agonists for the treatment of drug addiction: A review of recent findings. Drug Alcohol Depend. 2002;65(3):209-20.

  24. De Kloet SF, Mansvelder HD, De Vries TJ. Cholinergic modulation of dopamine pathways through nicotinic acetylcholine receptors. Biochem Pharmacol. 2015;97(4):425-38.

  25. Paterson NE, Froestl W, Markou A. Repeated administration of the GABAB receptor agonist CGP44532 decreased nicotine self-administration, and acute administration decreased cue-induced reinstatement of nicotine-seeking in rats. Neuropsychopharmacology. 2005;30(1):119-28.

  26. Forget B, Pushparaj A, Le Foll B. Granular insular cortex inactivation as a novel therapeutic strategy for nicotine addiction. Biol Psychiatry. 2010;68(3):265-71.

  27. Varani AP, Aso E, Moutinho R, Maldonado R, Balerio GN. Attenuation by baclofen of nicotine rewarding properties and nicotine withdrawal manifestations. Psychopharmacology (Berl). 2014;231(15):3031-40.

  28. Le Foll B, Wertheim CE, Goldberg SR. Effects of baclofen on conditioned rewarding and discriminative stimulus effects of nicotine in rats. Neuroscience Letters. 2008;443(3):236-40.

  29. Leggio L, Kenna GA, Swift RM. New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non-benzodiazepine GABAergic medications. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(5):1106-17.

  30. Walker BM, Koob GF. The gamma-aminobutyric acid-B receptor agonist baclofen attenuates responding for ethanol in ethanol-dependent rats. Alcohol Clin Exp Res. 2007;31(1):11-8.

  31. Chaudhri N, Sahuque LL, Schairer WW, Janak PH. Separable roles of the nucleus accumbens core and shell in context- and cue-induced alcohol- seeking. Neuropsychopharmacology. 2010;35(3):783-91.

  32. Colombo G, Addolorato G, Agabio R, Carai MA, Pibiri F, Serra S, et al. Role of GABA(B) receptor in alcohol dependence: reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics. Neurotox Res. 2004;6(5):403-14.

  33. Caine SB, Stevens NS, Mello NK, Bergman J. Effects of dopamine D1-like and D2-like agonists in rats that self-administer cocaine. The Journal of Pharmacology and Experimental Therapeutics. 1999;291:353-60.

  34. Voigt RM, Herrold AA, Napier TC. Baclofen facilitates the extinction of methamphetamine-induced conditioned place preference in rats. Behav Neurosci. 2011;125(2):261-7.

  35. Rocha A, Kalivas PW. Role of the prefrontal cortex and nucleus accumbens in reinstating methamphetamine seeking. Eur J Neurosci. 2010;31(5):903-9.

  36. Roberts CS, Andrews MM, Vickers GJ. Baclofen attenuates the reinforcing effects of cocaine in rats. Neurosychopharmacology. 1996;15:417-23.

  37. Brebner K, Phelan R, Roberts DC. Effect of baclofen on cocaine self-administration in rats reinforced under fixed-ratio 1 and progressive-ratio schedules. Psychopharmacology (Berl). 2000;148(3):314-21.

  38. Brebner K, Froestl W, Roberts DC. The GABA(B) antagonist CGP56433A attenuates the effect of baclofen on cocaine but not heroin self-administration in the rat. Psychopharmacology (Berl). 2002;160(1):49-55.

  39. Miranda F, Jiménez JC, Cedillo LN, Sandoval-Sánchez A, Millán-Mejía P, Sánchez-Castillo H, et al. The GABA-B antagonist 2-hydroxysaclofen reverses the effects of baclofen on the discriminative stimulus effects of D-amphetamine in the conditioned taste aversion procedure. Pharmacol Biochem Behav. 2009;93(1):25-30.

  40. Cedillo LN, Miranda F. Effects of co-administration of the GABAB receptor agonist baclofen and a positive allosteric modulator of the GABAB receptor, CGP7930, on the development and expression of amphetamine induced locomotor sensitization in rats. Pharmacological Reports. 2013;65(5):1132-43.

  41. Urwyler S. Allosteric modulators: The new generation of GABAB receptor ligands. En: Colombo G, editor. GABAB receptor. Suiza: Humana Press; 2016. p. 357-75.

  42. Mombereau C, Lhuillier L, Kaupmann K, Cryan JF. GABA(B) receptor-positive modulation-induced blockade of the rewarding properties of nicotine is associated with a reduction in nucleus accumbens DeltaFosB accumulation. J Pharmacol Exp Ther. 2007;321(1):172-7.

  43. Maccioni P, Vargiolu D, Thomas AW, Malherbe P, Corelli F, Leite-Morris KA, et al. Inhibition of alcohol self-administration by positive allosteric modulators of the GABAB receptor in rats: lack of tolerance and potentiation of baclofen. Psychopharmacology (Berl). 2015;232(10):1831-41.

  44. Augier E, Dulmas RS, Damadzic R, Pilling A, Hamilton JP, Heilig M. The GABAB Positive Allosteric Modulator ADX71441 Attenuates Alcohol Self-Administration and Alcohol Seeking in Rats. Neuropsychopharmacology. 2017;42(9):1789-99.

  45. Enserink, M. Addiction research. Anonymous alcoholic bankrolls trial of controversial therapy. Science. 2011;332(6030):653.

  46. Abhijit RR, Abhishek K, Ajeet S, Bir SC. Clinical experience of baclofen in alcohol dependence: a chart review. Ind Psychiatry J. 2016;25(1):11-6.

  47. Cousins MS, Stamat HM, De Wit H. Effects of a single dose of baclofen on selfreported subjective effects and tobacco smoking. Nicotine Tob Res. 2001;3(2):123-9.

  48. Ling W, Shoptaw S, Majewska D. Baclofen as a cocaine anti-craving medication: A preliminary clinical study. Neuropsychopharmacology. 1998;18(5):403-4.

  49. Addolorato G, Leggio L, Hopf FW, Diana M, Bonci A. Novel therapeutic strategies for alcohol and drug addiction: Focus on GABA, ion channels and transcranial magnetic stimulation. Neuropsychopharmacology. 2012;37(1):163-77.

  50. Ameinsen O. Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol Alcohol. 2005;40(2):147-50.

  51. Reynaud M, Aubin HJ, Trinquet F, Zakine B, Dano C, Dematteis M, et al. A randomized, placebo.controlled study of high-dose baclofen in alcohol- dependent patients-the ALPADIR study. Alcohol Alcohol. 2017;52(4):439-46.

  52. Brebner K, Childress AR, Roberts DCS. A potential role for GABA(B) agonists in the treatment of psychostimulant addiction. Alcohol Alcohol. 2002;37(5):478-84.




2020     |     www.medigraphic.com